Tilray shares closed at $6.14 on Wednesday, with trading volume reaching 7.3 million, above its 50-day average of 4.4 million.
This marks the second consecutive day of losses for Tilray, which now sits 73.53% below its 52-week high of $23.20 set on October 9.
The decline occurred during a session where the NASDAQ rose slightly but the Dow Jones fell, reflecting broader market uncertainty impacting Tilray's performance.
Medical marijuana is rescheduled, but is Tilray's stock still a value trap for investors?
Tilray bought BrewDog for a fraction of its value. What does this mean for small investors?
Will Tilray's big bet on craft beer save it from the struggling cannabis market?
With the US easing medical rules while banning hemp, how can Tilray navigate these contradictory policies?
As some states try to repeal cannabis laws, is the era of rapid market expansion over?